Abstracts tagged "scleroderma and systemic sclerosis"

Abstract Number: 688 • 2013 ACR/ARHP Annual Meeting
Minimal Clinically Important Investigations In Systemic Sclerosis
Jessica Meijs¹, Anne A. Schouffoer¹, Nina Ajmone Marsan², Maarten K. Ninaber³ and Tom W.J. Huizinga¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Cardiology, Leiden University Medical Center, Leiden, Netherlands, ³Pulmonology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The optimal management of Systemic Sclerosis (SSc) is a challenge due to the complexity of early diagnosis and identification of patients who are at…
Abstract Number: 674 • 2013 ACR/ARHP Annual Meeting
Systemic Sclerosis Disease Subset Is a Better Predictor Of Long Term Outcome Than Autoantibody Profile
Svetlana I. Nihtyanova¹, Voon H. Ong² and Christopher P. Denton³, ¹Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ²Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom, ³Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom
Background/Purpose: Disease subset has been shown to strongly correlate with survival and risk of organ complications in patients with systemic sclerosis (SSc). Nevertheless evidence in…
Abstract Number: 675 • 2013 ACR/ARHP Annual Meeting
Impact Of Male Sex On Survival In Systemic Sclerosis
Haseena Hussein¹, Peter Lee², Cathy Chau³ and Sindhu R. Johnson⁴, ¹Medicine, Toronto Scleroderma Research Program, Mount Sinai Hospital, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Lebovic Bldg, Mt. Sinai Hospital, Toronto, ON, Canada, ³Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Medicine, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) has a female predominance with a female-to-male ratio of 3:1. Sex differences have been seen in many autoimmune diseases; however, little…
Abstract Number: 680 • 2013 ACR/ARHP Annual Meeting
Diastolic Dysfunction Amongst Autoantibody Subgroups Of Patients With Diffuse Scleroderma
Cory Perugino¹, John Stephens², Colin O'Rourke³ and Soumya Chatterjee⁴, ¹Internal Medicine, Cleveland Clinic, Cleveland, OH, ²Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ³Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ⁴Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH
Background/Purpose: Scleroderma or systemic sclerosis (SSc) is an autoimmune disease characterized by microangiopathy, tissue hypoxia, and fibrosis. At least seven different autoantibodies have been identified…
Abstract Number: 2907 • 2013 ACR/ARHP Annual Meeting
D1398G Variant Of Hepatocyte Growth Factor Receptor – A Potential Biomarker Of Severe Interstitial Lung Disease In African American Scleroderma Patients
Ilia Atanelishvili¹, Tanjina Akter², Richard M. Silver³ and Galina S. Bogatkevich², ¹Division of Rheumatology & Immunology, Medical University of South Carolina,Charleston,USA, Charleston, SC, ²Department of Rheumatology, Medical University of South Carolina,Charleston,USA, Charleston, SC, ³Div Rheumatology & Immunology, Medical University of South Carolina,Charleston,USA, Charleston, SC
Background/Purpose: Interstitial lung disease (ILD) is a major complication and leading cause of mortality in scleroderma (SSc, systemic sclerosis). The morbidity and mortality rates in…
Abstract Number: 2917 • 2013 ACR/ARHP Annual Meeting
Mortality, Recurrence, and Hospital Course of Patients With Systemic Sclerosis Related Acute Intestinal Pseudo-Obstruction
Chris T. Derk¹, Nora Sandorfi², Shivani Purohit³ and Christopher Mecoli⁴, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, Thomas Jefferson Univ Med Coll, Philadelphia, PA, ³Rheumatology Division, Department of Medicine, Rheumatology Division, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, ⁴Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Acute intestinal pseudo-obstruction is a rare gastrointestinal manifestation of SSc with little data existing as to the demographics, clinical course, outcomes and mortality of…
Abstract Number: 2739 • 2013 ACR/ARHP Annual Meeting
Immunochip Analysis Identifies New Susceptibility Loci For Systemic Sclerosis: Implications For Pathogenesis
Maureen D. Mayes for the US Scleroderma GWAS Group¹, Lara Bossini-Castillo for the Spanish Scleroderma Group², Olga Gorlova³, Jose Ezequiel Martin⁴, Xiaodong Zhou¹, Wei Chen⁵, Shervin Assassi¹, Jun Ying⁵, John D. Reveille¹, Peter K. Gregersen⁶, Annette T. Lee⁷, Maria Teruel⁸, Francisco David Carmona⁴, Bobby P.C. Koeleman⁹, Matthew A. Brown and the Immunochip Consortium¹⁰, Christopher P. Denton¹¹, Murray Baron for the Canadian Scleroderma Research Group¹², Jasper Broen¹³, T.R.D.J. Radstake¹³ and Javier Martin⁴, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ³Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, ⁴Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, ⁵Department of Epidemiology, UT M.D. Anderson Cancer Center, Houston, TX, ⁶Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁷Genomics & Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁸Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ⁹Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁰Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ¹¹Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ¹²Rheumatology, Jewish General Hospital, Montreal, QC, Canada, ¹³Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose : The purpose of this study was to identify SSc risk loci shared with other autoimmune diseases on the Immunochip and to fine-map previously…
Abstract Number: 2609 • 2013 ACR/ARHP Annual Meeting
Dutch Translation and Validation Of The University of California, Los Angeles scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0
Jessica Meijs¹, Daisy Pors¹, Theodora P.M. Vliet Vlieland², Tom W.J. Huizinga¹ and Annemie J.M. Schuerwegh¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Orthopaedics, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Gastrointestinal tract (GIT) involvement occurs in approximately 90% of the patients with systemic sclerosis (SSc) and leads to a decrease in health-related quality of…
Abstract Number: 2582 • 2013 ACR/ARHP Annual Meeting
Treatment Of Pulmonary Hypertension In Scleroderma Patients With Restricitive Lung Disease.Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma Cohort
Virginia D. Steen¹ and Robyn T. Domsic², ¹Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ²Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Trials of therapy in pulmonary hypertension(PH) have generally excluded patients with significant interstitial lung disease, but many patients with systemic sclerosis(SSc) and PH have…
Abstract Number: 1712 • 2012 ACR/ARHP Annual Meeting
The Submaximal Heart and Pulmonary Evaluation: A Novel Noninvasive Test to Identify Pulmonary Hypertension in Patients with Systemic Sclerosis
Elana J. Bernstein¹, Jessica K. Gordon², Robert F. Spiera², Lisa A. Mandl² and Evelyn M. Horn³, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Cardiology, New York Presbyterian Hospital/Weill Cornell Medical College, New York, NY
Background/Purpose: Pulmonary hypertension (PH), defined as a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg on right heart catheterization (RHC), is a leading cause of…
Abstract Number: 1505 • 2012 ACR/ARHP Annual Meeting
Inactivation of Tankyrases Ameliorates Canonical Wnt Signaling and Prevents Experimental Fibrosis
Alfiya Distler¹, Lisa Deloch², Jingang Huang², Clara Dees², Neng Yu Lin², Christian Beyer³, Oliver Distler⁴, Georg A. Schett⁵ and Joerg HW Distler¹, ¹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine 3, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Systemic sclerosis (SSc) is characterized by aberrant activation of fibroblasts with increased release of extracellular matrix components. Canonical Wnt signaling has recently emerged as…
Abstract Number: 1464 • 2012 ACR/ARHP Annual Meeting
Comparison of Baseline Characteristics of the Combined Response Index for Systemic Sclerosis (CRISS) Cohort to Patients Enrolled in Clinical Trials of Diffuse Systemic Sclerosis
Heather Gladue¹, Daniel Furst², Veronica Berrocal³, James R. Seibold⁴, Peter A. Merkel⁵, Maureen D. Mayes⁶, Kristine Phillips⁷, Robert W. Simms⁸, Shervin Assassi⁹, Philip J. Clements¹⁰, Paul Maranian¹¹ and Dinesh Khanna¹², ¹University of Michigan, Ann Arbor, MI, ²David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ³Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Scleroderma Research Consultants LLC, Avon, CT, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁷Rheumatology, University of Michigan Medical School, Ann Arbor, MI, ⁸Rheumatology, Boston University School of Medicine, Boston, MA, ⁹Rheumatology, Univ of Texas Health Science Houston, Houston, TX, ¹⁰University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ¹¹Division of Rheumatology, UCLA Medical School, Los Angeles, CA, ¹²Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Randomized clinical trials (RCTs) of treatment of diffuse systemic sclerosis (dcSSc) would benefit from a composite index that predicted efficacy better than current standard…
Abstract Number: 1470 • 2012 ACR/ARHP Annual Meeting
Clinical Features Associated with Anti-Th/to in Non-Scleroderma Patients – Sine Scleroderma?
Ann D. Chauffe¹, Minoru Satoh¹, Angela Ceribelli², Edward K.L. Chan², Yi Li¹, Eric S. Sobel³, Westley H. Reeves⁴ and Michael R. Bubb¹, ¹Medicine, University of Florida, Gainesville, FL, ²Oral Biology, University of Florida, Gainesville, FL, ³Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, ⁴Rheumatology & Clinical Imm, University of Florida, Gainesville, FL
Background/Purpose: Autoantibodies in scleroderma (systemic sclerosis, SSc) such as anti-topoisomerase I (Scl-70), RNA polymerase III, centromere, U3RNP/fibrillarin, and Th/To are associated with a unique subset…
Abstract Number: 853 • 2012 ACR/ARHP Annual Meeting
Systemic Sclerosis Classification Criteria: Developing Methods for Multi-Criteria Decision Analysis
Sindhu R. Johnson¹, Raymond P. Naden², Jaap Fransen³, Frank H.J. van den Hoogen⁴, Janet E. Pope⁵, Murray Baron⁶, Alan G. Tyndall⁷, Marco Matucci-Cerinic⁸ and Dinesh Khanna on behalf of ACR/EULAR Classification Criteria SSc⁹, ¹Dept of Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²Auckland City Hospital, Auckland, New Zealand, Austria, ³Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, ⁵Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁶Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁷Rheumatology, University of Basel, Basel, Switzerland, ⁸Medicine, Univ Florence, Firenze, Italy, ⁹Div of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Classification criteria for systemic sclerosis (SSc) are being developed. Twenty-three candidate criteria have been identified, but need to be reduced. The objectives of this…
Abstract Number: 711 • 2012 ACR/ARHP Annual Meeting
Myopathy Is a Poor Prognostic Feature in Systemic Sclerosis: Results From the Canadian Scleroderma Research Group
MIchelle Jung¹, Murray Baron², Marie Hudson³, Ashley Bonner⁴, Janet E. Pope⁵ and Canadian Scleroderma Research Group⁶, ¹Western University, London, ON, Canada, ²Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³Jewish General Hospital, McGill University, Montreal, QC, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁶Montreal, QC, Canada
Background/Purpose: Myopathy / myositis is associated with more severe systemic scleroderma (SSc). The aim of this study was to determine such clinical information from the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].